Background and objectives:Knee osteoarthritis is the most common joint disease. We aimed to compare the efficacy and safety of intra-articular injection of a newly developed plasma rich in growth factor (PRGF) versus hyaluronic acid (HA) on pain and function of patients with knee osteoarthritis.Methods:In this single-blinded randomized clinical trial, patients with symptomatic osteoarthritis of knee were assigned to receive 2 intra-articular injections of our newly developed PRGF in 3 weeks or 3 weekly injections of HA. Our primary outcome was the mean change from baseline until 2 and 6 months post intervention in scores of visual analog scale, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Lequesne index. We used analysis of variance for repeated-measures statistical test.Results:A total of 69 patients entered final analysis. The mean age of patients was 58.2 ± 7.41 years and 81.2% were women. In particular, total WOMAC index decreased from 42.9 ± 13.51 to 26.8 ± 13.45 and 24.4 ± 16.54 at 2 and 6 months in the newly developed PRGF group (within subjects P = .001), and from 38.8 ± 12.62 to 27.8 ± 11.01 and 27.4 ± 11.38 at 2 and 6 months in the HA group (within subjects P = .001), respectively (between subjects P = .631). There was no significant difference between PRGF and HA groups in patients’ satisfaction and minor complications of injection, whereas patients in HA group reported significantly lower injection-induced pain.Conclusions:In 6 months follow up, our newly developed PRGF and HA, both are effective options to decrease pain and improvement of function in patients with symptomatic mild to moderate knee osteoarthritis.

Background Our study compare the short and long-term efficacy of the intra articular injections (IAIs) of hyaluronic acid (HA), platelet-rich plasma (PRP), plasma rich in growth factors (PRGF), and ozone in patients with knee osteoarthritis (OA). Methods In this randomized clinical trial, 238 patients with mild to moderate knee OA were randomized into 4 groups of IAIs: HA (3 doses weekly), PRP (2 doses with 3 weeks interval), PRGF (2 doses with 3 weeks interval), and Ozone (3 doses weekly). Our outcome measures were the mean changes from baseline (immediately from the first injections) until 2,6, and 12 months post intervention in scores of visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Lequesne index. Results A total of 200 patients enrolled in the final analysis. The mean age of patients was 56.9 ± 6.3 years, and 69.5% were women. In 2 months follow up, significant improvement of pain, stiffness, and function were seen in all groups compared to the baseline, but the ozone group had the best results (P < 0.05). In 6 month follow up HA, PRP, and PRGF groups demonstrated better therapeutic effects in all scores in comparison with ozone (P < 0.05). At the end of the 12th month, only PRGF and PRP groups had better results versus HA and ozone groups in all scores (P < 0.05). Despite the fact that ozone showed better early results, its effects begin to wear off earlier than other products and ultimately disappear in 12 months. Conclusions Ozone injection had rapid effects and better short-term results after 2 months, but its therapeutic effects did not persist after 6 months and at the 6-month follow up, PRP,PRGF and HA were superior to ozone. Only patients in PRP and PRGF groups improved symptoms persisted for 12 months. Therefore, these products could be the preferable choices for long-term management. Trial registration Registered in the Iranian Center of Clinical Trials (www.irct.ir) in 11/11/2017 with the following code: IRCT2017082013442N17.

In this study, we aimed at performing a comparison between intra-articular injections of PRP-derived growth factor (PGRF) and hyaluronic acid regarding their effect on pain and patient's function in knee osteoarthritis, as well as their safety profiles. Methods: During our single-masked randomized clinical trial, the candidates with symptomatic knee osteoarthritis received two intra-articular injections of PRGF with 3 weeks apart or received three weekly injections of HA. The mean improvements from before treatment until the second, sixth, and twelfth months post-intervention in scores obtained by visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Lequesne index were our primary outcomes. Results: A total of 102 candidates were finally included in the study. Patients' mean age was 57.08 ±7.3 years old in the PRGF group compared to the mean age of 58.63±7.09 years old in HA patients. In the PRGF group, total WOMAC index decreased from 41.96±11.71 to 27.10±12.3 (P = 0.02), and from 39.71±10.4 to 32.41±11.8 in the HA group after 12 months (P > 0.05). Regarding the Lequesne index, pain, ADL, and global scores significantly decreased after 12 months in the PRGF group compared to the HA group (P<0.001). There was also a meaningful higher rate of satisfaction in the PRGF group compared to the HA group after 12 months of treatment (P<0.001). Conclusion: Besides significantly higher satisfaction belonging to the PRGF group, there was a statistically significant improvement in VAS score and global, pain, and ADL score of Lequesne by passing 12 months from injection in PRGF compared to HA.

Background:Knee osteoarthritis (OA) as a common progressive degenerative condition is one of the most important leading causes of disability and relative dependence. Worldwide prevalence of symptomatic knee OA has estimated 3.8%. It affects more than 20% of over 45-year-old population. Among the minimally invasive methods recommended for knee OA management is intra-articular injections for which a large array of products have been used. Despite all the existing options, there is still no general consensus on the choice and priority of the best intra-articular injection in knee osteoarthritis.Objectives:Our study compare the short and long-term efficacy of the intra articular injections (IAIs) of hyaluronic acid (HA), platelet-rich plasma (PRP), plasma rich in growth factors (PRGF), and ozone in patients with knee osteoarthritis (OA).Methods:In this single-blinded randomized clinical trial, 238 patients with mild to moderate knee OA were randomized into4 groups of IAIs: HA (3 doses weekly), PRP (2 doses with 3 weeks interval), PRGF (2 doses with 3 weeks interval), and Ozone (3 doses weekly). Our outcome measures were the mean changes from baseline until 2,6, and 12 months post intervention in scores of visual analog scale, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Lequesne index.Results:A total of 200 patients enrolled final analysis. The mean age of patients was 56.9 ± 6.3 years, and69.5% were women. In 2 months follow up, significant improvement of pain, stiffness, and function were seen in all groups compared to the baseline, but the ozone group had the best results(P<0.05). In 6 month follow up HA, PRP, and PRGF groups demonstrated better therapeutic effects in all scores in comparison with ozone (P<0.05).At the end of the 12th month, only PRGF and PRP groups had better results versus HA and ozone groups in all scores (P<0.05).Despite the fact that ozone showed better early results, its effects begin to wear off earlier than other products and ultimately disappear in 12 months.Conclusion:Ozone injection had rapid effects and better short-term results after 2 months, but its therapeutic effects did not persist after 6 months and at the 6-month follow up, PRP,PRGF and HA were superior to ozone. Only patients in PRP and PRGF groups improved symptoms persisted for 12 months. Therefore, these products could be the preferable choices for long-term management.References:[1]Wang-Saegusa A, Cugat R, Ares O, Seijas R, Cuscó X, Garcia-Balletbó M. Infiltration of plasma rich in growth factors for osteoarthritis of the knee short-term effects on function and quality of life. Archives of orthopaedic and trauma surgery. 2011;131(3):311-7.[2]De La Mata J. Platelet rich plasma.A new treatment tool for the rheumatologist?ReumatologíaClínica (English Edition). 2013;9(3):166-71.[3]Raeissadat SA, Rayegani SM, Sedighipour L, Bossaghzade Z, Abdollahzadeh MH, Nikray R, et al. The efficacy of electromyographic biofeedback on pain, function, and maximal thickness of vastus medialis oblique muscle in patients with knee osteoarthritis: a randomized clinical trial. Journal of pain research. 2018;11:2781.[4]Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis & Rheumatism. 2008;58(1):26-35.[5]Tehrani-Banihashemi A, Davatchi F, Jamshidi AR, Faezi T, Paragomi P, Barghamdi M. Prevalence of osteoarthritis in rural areas of I ran: a WHO-ILAR COPCORD study. International journal of rheumatic diseases. 2014;17(4):384-8.[6]Rayegani SM, Raeissadat SA, Heidari S, Moradi-Joo M. Safety and effectiveness of low-level laser therapy in patients with knee osteoarthritis: a systematic review and meta-analysis. Journal of lasers in medical sciences. 2017;8(Suppl 1):S12.Disclosure of Interests:None declared

BackgroundOsteoarthritis (OA) is the most common joint disease with characteristics of progressive loss of joint cartilage.ObjectivesAim of this study was to evaluate clinical outcomes of intra-articular injection of PRP derived growth factor (PRGF) versus hyaluronic acid (HA) in patients with knee osteoarthritis.Methods102 patients with grade П or grade Ш knee OA were randomly assigned to 2 intra-articular injections of PRGF 3 weeks apart or 3 weekly injections of HA. Primary outcome was the mean change from baseline until 2, 6 and 12 months post intervention in scores of visual analog scale (VAS), WOMAC and Lequesne index.ResultsThe mean age of patients was 57.08±7.3 in PRGF compared to 58.63±7.09 in HA group. In PRGF group, VAS decreased from 7.8±1.5 to 4.5±1.7, and from 7.8±1.1 to 6.1±1.8 in the HA group after 12 months (P<0.0001). Total WOMAC score decreased from 41.96±11.71 to 27.10±12.3 (P = 0.02), and from 39.71±10.4 to 32.41±11.8 after 12 months, respectively (P > 0.05). In Lequesne index, all scores were significantly decreased after 12 months in PRGF group in comparison to HA group (P<0.001).ConclusionAlthough PRGF and HA were both effective, but PRGF injection resulted in significantly higher satisfaction, lower VAS and Lequesne pain score and improvement in function of patients with symptomatic mild to moderate knee osteoarthritis.References[1] Raeissadat SA, Rayegani SM, Tabibian E, Rahimi Dehgolan S. Intra-articular ozone injection efficacy in knee osteoarthritis: A systematic review with meta-analysis. Annals of Physical and Rehabilitation Medicine. 2018;61:e132-e3.[2] Raeissadat SA, Rayegani SM, Hassanabadi H, Fathi M, Ghorbani E, Babaee M, et al. Knee Osteoarthritis Injection Choices: Platelet- Rich Plasma (PRP) versus Hyaluronic Acid (A one-year randomized clinical trial). Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. 2015;8:CMAMD.S17894.[3] Raeissadat SA, Rayegani SM, Ahangar AG, Abadi PH, Mojgani P, Ahangar OG. Efficacy of Intra-articular Injection of a Newly Developed Plasma Rich in Growth Factor (PRGF) Versus Hyaluronic Acid on Pain and Function of Patients with Knee Osteoarthritis: A Single-Blinded Randomized Clinical Trial. Clinical medicine insights Arthritis and musculoskeletal disorders. 2017;10:1179544117733452.Abstract THU0422 – Figure 1Mean values of Lequesne total at baseline, 2, 6 and 12 months after injection. PRGF indicates plasma rich in growth factorDisclosure of InterestsNone declaredAbstract THU0422 – Table 2WOMAC and VAS mean scores at baseline, 2, 6 and 12 months after injection. WOMAC index PainStiffnessFunctionTotalVASPRGFHAPRGFHAPRGFHAPRGFHAPRGFHABaseline8.25±2.78.14±2.62.86±1.82.57±.1.430.75±8.529±8.141.96±11.7139.71±10.47.8±1.57.8±1.1At 2 mo4.98±2.65.31±2.31.53±1.41.2±1.119.75±8.220.78±6.626.25±11.1727.37±9.094.2±2.014.4±1.6At 6 mo5.22±3.055.9±2.31.43±1.51.2±1.218.22±9.921.12±6.624.86±1428.35±9.44.3±2.34.7±1.9At 12 mo5.47±2.66.3±2.61.8±1.341.6±1.219.82±8.924.43±8.4 b27.10±12.332.41±11.84.5±1.76.1±1.8P-value Within groups<0.0001<0.0001<0.0001<0.00...

BackgroundKnee osteoarthritis is the most common joint disease.ObjectivesWe aimed to compare the efficacy and safety of intra-articular injection of PRP-drived growth factor versus hyaluronic acid (HA) on pain and function of patients with knee osteoarthritis.MethodsIn this single-blinded randomised clinical trial, patients with symptomatic osteoarthritis of knee were assigned to receive 2 intra-articular injections of PRP-drived growth factor in 3  weeks or 3 weekly injections of HA. Our primary outcome was the mean change from baseline until 2 and 6  months post intervention in scores of visual analogue scale, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Lequesne index.ResultsA total of 69 patients entered final analysis. The mean age of patients was 58.2 ± 7.41  years and 81.2% were women. Total WOMAC index decreased from 42.9 ± 13.51 to 26.8 ± 13.45 and 24.4 ± 16.54 at 2 and 6  months in the PRGF group (within subjects p = 0.001), and from 38.8 ± 12.62 to 27.8 ± 11.01 and 27.4 ± 11.38 at 2 and 6  months in the HA group (within subjects p = 0.001), respectively (between subjects p = 0.631). There was no significant difference between PRP-drived growth factor and HA groups in patients’ satisfaction and minor complications of injection, whereas patients in HA group reported significantly lower injection-induced pain.Abstract AB0976 – Table 1WOMAC scoresVAS PainFunctionStiffnessTotal PRGFBaseline9.2±2.9730.6±10.093.0±2.0142.9±13.517.8±1.78At 2 month5.8±2.9619.5±9.791.6±1.6626.8±13.454.9±2.21At 6 month5.3±3.6017.6±11.701.5±1.8424.4±16.544.6±2.78P value within groups0.00010.00010.00010.00010.0001HyalganBaseline8.7±3.0127.8±9.622.3±1.6438.8±12.627.4±1.48At 2 month5.9±2.6520.6±8.041.2±1.3927.8±11.014.8±1.80At 6 month5.9±2.7920.1±7.771.3±1.4827.4±11.384.8±2.39P value within groups0.00010.00010.00010.00010.0001P value Between Groups0.8470.8940.1890.9850.648Abstract AB0976 – Figure 1ConclusionsIn 6 months follow up, PRP-drived growth factor and HA, both are effective options to decrease pain and improvement of function in patients with mild to moderate knee osteoarthritis.References[1] Raeissadat, SA, Babaee, M, Rayegani, SM. An overview of platelet products (PRP, PRGF, PRF, etc.) in the Iranian studies [published onlineahead of print July 28, 2017]. Futur Sci OA. doi:10.4155/fsoa-2017-0045.[2] Raeissadat, SA, Rayegani, SM, Babaee, M, Ghorbani, E. The effect of platelet-rich plasma on pain, function, and quality of life of patients with knee osteoarthritis. Pain Res Treat. 2013;2013:165967. Google Scholar[3] Raeissadat, SA, Rayegani, SM, Hassanabadi, H. Knee osteoarthritis injection choices: platelet-rich plasma (PRP) versus hyaluronic acid (a one-year randomized clinical trial). Clin Med Insights Arthritis Musculoskelet Disord. 2015;8:1–8.[4] Raeissadat SA, Rayegani SM, Moridnia M, Dehgolan SR. Intra articular ozone or hyaluronic acid injection: which one is superior in patients with knee osteoarthritis? a 6-month randomized clinical trial.Annals of the Rheumatic Diseases2017;76(Suppl 2):1...